Sanofi-Aventis to end deal with PDI

Share this article:
Contract sales provider PDI said Sanofi-Aventis would end its $20 million sales agreement with the firm, effective Dec. 1. The deal was set to expire Dec. 31, PDI said. The end of the firm’s Sanofi-Aventis deal comes a month after GlaxoSmithKline decided not to renew a $65 million to $70 million contract with PDI for 2007. In April, AstraZeneca also ended a $65 million to $70 million agreement with PDI, affecting approximately 800 field representatives. PDI “has been significantly impacted” as the world’s top pharma companies re-evaluate their commercial models, CEO Michael Marquad said in a statement. “The decisions our customers have made have been based upon this reassessment and not related to the performance of our sales teams.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, ...

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.